Drug Trial Radar · NCT05399069
Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy
Last checked: Nov 19, 2026Latest source record: Nov 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3
Planned (sponsor's estimate)
Start
Sep 15, 2022
Primary completion
May 2024
Study completion May 2024
Sponsor
- Lead sponsor
- Beijing Tongren HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-Label, Non-Randomized, Uncontrolled, Single-dose Pilot Study of VGR-R01 in Patients with Bietti Crystalline Dystrophy.
Conditions
- Bietti Crystalline Dystrophy
Interventions
VGR-R01Drug
Gene Replacement Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Baseline up to Day 365
- Incidence of serious adverse eventsTime frame: Baseline up to Day 365
- Number of Participants with Clinically Significant Change from Baseline in Vital SignsTime frame: Baseline up to Day 365
- Number of Participants with Clinically Laboratory AbnormalitiesTime frame: Baseline up to Day 365
- Number of Participants with Clinically Significant Change from Baseline in Ophthalmic Examination FindingsTime frame: Baseline up to Day 365
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.